- Trials with a EudraCT protocol (1,699)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,699 result(s) found for: Point of care.
Displaying page 8 of 85.
EudraCT Number: 2022-001152-42 | Sponsor Protocol Number: ShaperonC002 | Start Date*: 2022-09-05 | |||||||||||
Sponsor Name:Shaperon, Inc. | |||||||||||||
Full Title: A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID... | |||||||||||||
Medical condition: COVID-19 Pneumonia Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) HR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006309-96 | Sponsor Protocol Number: 0881A6-3326 | Start Date*: 2007-06-08 |
Sponsor Name:Wyeth Pharmaceuticals France | ||
Full Title: A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjecto... | ||
Medical condition: PSORIASIS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) BE (Completed) FI (Completed) ES (Completed) DE (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002188-13 | Sponsor Protocol Number: UoL001087 | Start Date*: 2015-03-03 | |||||||||||
Sponsor Name:University of Liverpool [...] | |||||||||||||
Full Title: Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial | |||||||||||||
Medical condition: Convulsive Status Epilepticus | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003867-79 | Sponsor Protocol Number: IDTX-MA-3004 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | |||||||||||||
Medical condition: Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004424-65 | Sponsor Protocol Number: 15085MS-AS | Start Date*: 2016-05-09 |
Sponsor Name:Belfast Health and Social Care Trust | ||
Full Title: Prevention of post-operative complications by using HMG-CoA Reductase Inhibitor in patients undergoing oesophagectomy - A multicentre, randomised, double blind, placebo controlled trial | ||
Medical condition: Post-operative complications - Post-operative Pulmonary complication, Acute Respiratory Distress Syndrome and Myocardial Infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2016-002688-32 | Sponsor Protocol Number: 1602T0832 | Start Date*: 2017-11-07 | |||||||||||||||||||||
Sponsor Name:Shionogi Ltd. | |||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Infl... | |||||||||||||||||||||||
Medical condition: Influenza | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) LV (Completed) HU (Completed) GB (Completed) PL (Completed) BG (Completed) ES (Completed) BE (Completed) RO (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000106-22 | Sponsor Protocol Number: GE012-098 | Start Date*: 2011-09-01 | |||||||||||||||||||||
Sponsor Name:GE Healthcare Ltd. and its affiliates | |||||||||||||||||||||||
Full Title: A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography | |||||||||||||||||||||||
Medical condition: Patients that are referred to undergo a peripheral arterigraphy as part of their routine clinical care. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003328-56 | Sponsor Protocol Number: CTU/2014/107 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:University College London Comprehensive Clinical Trials Unit | |||||||||||||
Full Title: A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progres... | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004648-12 | Sponsor Protocol Number: CLS1003-301 | Start Date*: 2018-01-15 |
Sponsor Name:Clearside Biomedical, Inc. | ||
Full Title: SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION | ||
Medical condition: Retinal Vein Occlusion | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) HU (Completed) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) PT (Completed) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005694-31 | Sponsor Protocol Number: 2012/ADE002 | Start Date*: 2013-07-05 | |||||||||||
Sponsor Name:Adenovir Pharma AB | |||||||||||||
Full Title: Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Mult... | |||||||||||||
Medical condition: Acute phase Adenoviral-induced Epidemic Keratoconjunctivitis, EKC | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002089-37 | Sponsor Protocol Number: CLS1003-302 | Start Date*: 2018-09-27 |
Sponsor Name:Clearside Biomedical, Inc. | ||
Full Title: TOPAZ: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION | ||
Medical condition: Retinal Vein Occlusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) HU (Completed) EE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-002981-64 | Sponsor Protocol Number: CC-10004-UC-001 | Start Date*: 2015-08-13 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS | |||||||||||||
Medical condition: Subjects with active ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023612-14 | Sponsor Protocol Number: N/A | Start Date*: 2013-03-08 | |||||||||||
Sponsor Name:Clinical Trials and Research Governance | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic reso... | |||||||||||||
Medical condition: Marfan syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001107-20 | Sponsor Protocol Number: MDT-637-CP-201 | Start Date*: 2013-08-02 | |||||||||||
Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd. | |||||||||||||
Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b) | |||||||||||||
Medical condition: RSV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003578-24 | Sponsor Protocol Number: FE 200486 CS25 | Start Date*: 2008-06-30 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A single-centre, open-label, randomised explorative pharmacokinetic/pharmacodynamic study of the gonadotropin-releasing hormone receptor antagonist degarelix (FE 200486) in patients with benign pro... | |||||||||||||
Medical condition: Patients with Benign Prostata Hypertropia (BPH) who fulfil the following criteria: a prostate volume of more than 30 mL, maximal uroflow of 12 mL/s or less; International Prostate Symptom Score (IP... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005351-27 | Sponsor Protocol Number: 2015CD007B | Start Date*: 2016-02-17 | ||||||||||||||||
Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust | ||||||||||||||||||
Full Title: A randomised controlled pilot trial of the feasibility and safety of therapy withdrawal in asymptomatic patients with a prior diagnosis of dilated cardiomyopathy & recovered cardiac function. | ||||||||||||||||||
Medical condition: Dilated Cardiomyopathy with recovered cardiac function | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003921-13 | Sponsor Protocol Number: 12/0368 | Start Date*: 2013-06-07 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: COMbination therapy for PulmonAry hypertension using RacEcadotril (COMPARE). | |||||||||||||
Medical condition: Pulmonary hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005483-21 | Sponsor Protocol Number: 15-2021 | Start Date*: 2022-01-05 |
Sponsor Name:Akershus University Hospital | ||
Full Title: Chiropractic spinal manipulative therapy for acute neck pain: a 4-armed clinical placebo randomized controlled trial | ||
Medical condition: Acute neck pain | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003013-34 | Sponsor Protocol Number: UOL0730 | Start Date*: 2020-03-02 | ||||||||||||||||||||||||||
Sponsor Name:University of Leicester | ||||||||||||||||||||||||||||
Full Title: Beyond Allergic Th2 Severe Asthma | ||||||||||||||||||||||||||||
Medical condition: T2-High and T2-Low severe asthma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001805-21 | Sponsor Protocol Number: RA486120 | Start Date*: 2020-05-15 |
Sponsor Name:University Hospital Coventry & Warwickshire | ||
Full Title: Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 | ||
Medical condition: Sars-Cov-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
